Ming Lee
@drmjlee.bsky.social
Cat dad. Sexual Health and HIV doctor. He/Him 🏳️🌈
Pinned
Ming Lee
@drmjlee.bsky.social
· Apr 10
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
Reposted by Ming Lee
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
April 23, 2025 at 8:07 AM
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
Reposted by Ming Lee
i-base.info/htb/50971
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
The RIO study: Q&A about controlling HIV with bNAbs | HTB | HIV i-Base
i-base.info
April 23, 2025 at 11:41 AM
i-base.info/htb/50971
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
April 10, 2025 at 7:23 AM
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
At the Keystone HIV cure symposium in Durban, South Africa. Looking forward to a great line up of talks and the chance to meet other cure researchers around the globe!
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
April 8, 2025 at 7:01 AM
At the Keystone HIV cure symposium in Durban, South Africa. Looking forward to a great line up of talks and the chance to meet other cure researchers around the globe!
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
Reposted by Ming Lee
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
March 13, 2025 at 12:16 PM
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
4mthly IV/SC N6LS with mthly CAB maintained viral suppression, but there were a small but significant group of people who experienced viral control failure.
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
March 12, 2025 at 7:58 PM
4mthly IV/SC N6LS with mthly CAB maintained viral suppression, but there were a small but significant group of people who experienced viral control failure.
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Reposted by Ming Lee
96W CARES CAB/RPV. Efficacy remains high and non-inferior vs continued oral ART (97% <50)
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
March 12, 2025 at 7:40 PM
96W CARES CAB/RPV. Efficacy remains high and non-inferior vs continued oral ART (97% <50)
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced.
Great results.
Tecovirimat did not lead to faster clinical resolution, or reduction of pain, for clade 2 MPOX.
We need new agents to treat MPOX.
#CROI2025
We need new agents to treat MPOX.
#CROI2025
March 12, 2025 at 7:31 PM
Tecovirimat did not lead to faster clinical resolution, or reduction of pain, for clade 2 MPOX.
We need new agents to treat MPOX.
#CROI2025
We need new agents to treat MPOX.
#CROI2025
Frailty was associated with an increased risk of MACE in the REPRIEVE study. However frailty did not seem to impact the effectiveness of pitavastatin on preventing MACE outcomes.
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
March 12, 2025 at 6:11 PM
Frailty was associated with an increased risk of MACE in the REPRIEVE study. However frailty did not seem to impact the effectiveness of pitavastatin on preventing MACE outcomes.
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Findings from the last gift cohort. Although total HIV DNA measures were similar in the spinal cord (SC) compared to the brain, there was higher HIV diversity seen in the SC. SC may be an important site of HIV dispersal. #CROI2025
March 12, 2025 at 6:08 PM
Findings from the last gift cohort. Although total HIV DNA measures were similar in the spinal cord (SC) compared to the brain, there was higher HIV diversity seen in the SC. SC may be an important site of HIV dispersal. #CROI2025
Reposted by Ming Lee
A real challenge in this field is being able to carefully examine brain and central nervous system tissues over time. People may consent to lumbar punctures but a (or multiple) brain biopsy is much more invasive. Studies like the Last Gift are truly amazing but only allow tissue study after death.
March 12, 2025 at 5:44 PM
A real challenge in this field is being able to carefully examine brain and central nervous system tissues over time. People may consent to lumbar punctures but a (or multiple) brain biopsy is much more invasive. Studies like the Last Gift are truly amazing but only allow tissue study after death.
Reposted by Ming Lee
Took a break from science news to write up Monday's inspiring #SaveOurSciences rally at #CROI2025. More of a photo essay, really, with lots of familiar faces.
www.poz.com/article/hiv-...
www.poz.com/article/hiv-...
HIV Researchers and Advocates Rally to Save Our Sciences
Speakers oppose the Trump administration’s funding cuts to the NIH, PEPFAR and Medicaid and attacks on communities most vulnerable to HIV.
www.poz.com
March 12, 2025 at 4:20 PM
Took a break from science news to write up Monday's inspiring #SaveOurSciences rally at #CROI2025. More of a photo essay, really, with lots of familiar faces.
www.poz.com/article/hiv-...
www.poz.com/article/hiv-...
Roger Paredes on Long COVID. Lots of evidence now that viral persistence seen up to 2yrs after initial infection is seen in people with long COVID. LC is associated with increased thromboinflammation.
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
March 12, 2025 at 4:14 PM
Roger Paredes on Long COVID. Lots of evidence now that viral persistence seen up to 2yrs after initial infection is seen in people with long COVID. LC is associated with increased thromboinflammation.
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
It's great to see two more people reported to be in remission from HIV after stem cell transplants at #CROI2025.
But stem cell transplants remain a high risk procedure and not feasible for all, and we need safer, more scalable and accessible cure interventions for people living with HIV.
But stem cell transplants remain a high risk procedure and not feasible for all, and we need safer, more scalable and accessible cure interventions for people living with HIV.
News from #CROI2025: Two more people appear to be free of HIV after stem cell transplants for cancer treatment. If these men remain in remission, they will be the 8th & 9th known cases of a functional cure after the procedure.
www.poz.com/article/two-...
www.poz.com/article/two-...
Two More People May Be Cured of HIV After Stem Cell Transplants
One experienced viral rebound after an initial treatment interruption but remains in remission after stopping antiretrovirals a second time.
www.poz.com
March 12, 2025 at 4:04 PM
It's great to see two more people reported to be in remission from HIV after stem cell transplants at #CROI2025.
But stem cell transplants remain a high risk procedure and not feasible for all, and we need safer, more scalable and accessible cure interventions for people living with HIV.
But stem cell transplants remain a high risk procedure and not feasible for all, and we need safer, more scalable and accessible cure interventions for people living with HIV.
Reposted by Ming Lee
A must-watch: Rebecca Denison, founder of Women Organized to Respond to Life-threatening Diseases (WORLD), delivers the Martin Delaney Presentation at #CROI2025
"40+ Years of #HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must"
Thanks to IAS-USA for making it publicly available.
"40+ Years of #HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must"
Thanks to IAS-USA for making it publicly available.
40+ Years of HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must
YouTube video by IAS-USA
youtu.be
March 12, 2025 at 5:09 AM
Reposted by Ming Lee
You can find out more about the latest study developments at riotrial.org
RIO HIV Trial - Viral suppression off ART using dual bNAb therapy
RIO is looking at whether a new type of treatment, called bNAbs can keep viral load undetectable without antiretroviral treatment (ART)
riotrial.org
March 11, 2025 at 7:21 PM
You can find out more about the latest study developments at riotrial.org
Reposted by Ming Lee
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
CROI 2025 Monday (March 10) Press Conference
YouTube video by IAS-USA
www.youtube.com
March 11, 2025 at 7:24 PM
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
Reposted by Ming Lee
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
March 11, 2025 at 1:37 PM
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Really exciting data on once yearly Lenacapravir. Safe and well tolerated with little injection site reactions, pain reduced with with pre treatment ice. Trough levels higher than twice yearly formulations.
Potentially helpful for pairing with other long acting rx eg. bNAbs in the future?
Potentially helpful for pairing with other long acting rx eg. bNAbs in the future?
PK/safety of ONCE YEARLY LEN! Potential to address LEN barriers. Two IM formulations (F1/2) assessed in HIV-neg ppl.
Tmax F1 12W, good PK to W56 & higher than Q6M LEN. F2 similar. Both safe/well-tolerated. NO NODULES!!!! Pre-treatment ice reduced injection pain.
This is exciting?!?!??!
#CROI2025
Tmax F1 12W, good PK to W56 & higher than Q6M LEN. F2 similar. Both safe/well-tolerated. NO NODULES!!!! Pre-treatment ice reduced injection pain.
This is exciting?!?!??!
#CROI2025
March 11, 2025 at 5:49 PM
Really exciting data on once yearly Lenacapravir. Safe and well tolerated with little injection site reactions, pain reduced with with pre treatment ice. Trough levels higher than twice yearly formulations.
Potentially helpful for pairing with other long acting rx eg. bNAbs in the future?
Potentially helpful for pairing with other long acting rx eg. bNAbs in the future?
Reposted by Ming Lee
1st Q down at #CROI2025!
Q: In RIO (bNAbs vs placebo in VS ppl undergoing ATI) how were co-morbidities excluded (18% with rebound in the bNAb arm had VLs >1m & we know, e.g. in REPRIEVE, lots of subclinical CAD)?
A: Sarah Fidler - RIO young pop. In future biomarkers or more invasive tests may help
Q: In RIO (bNAbs vs placebo in VS ppl undergoing ATI) how were co-morbidities excluded (18% with rebound in the bNAb arm had VLs >1m & we know, e.g. in REPRIEVE, lots of subclinical CAD)?
A: Sarah Fidler - RIO young pop. In future biomarkers or more invasive tests may help
March 10, 2025 at 6:45 PM
1st Q down at #CROI2025!
Q: In RIO (bNAbs vs placebo in VS ppl undergoing ATI) how were co-morbidities excluded (18% with rebound in the bNAb arm had VLs >1m & we know, e.g. in REPRIEVE, lots of subclinical CAD)?
A: Sarah Fidler - RIO young pop. In future biomarkers or more invasive tests may help
Q: In RIO (bNAbs vs placebo in VS ppl undergoing ATI) how were co-morbidities excluded (18% with rebound in the bNAb arm had VLs >1m & we know, e.g. in REPRIEVE, lots of subclinical CAD)?
A: Sarah Fidler - RIO young pop. In future biomarkers or more invasive tests may help
At the Stand up for science protest yesterday. There was anger, there was determination. As researchers, clinicians, and activists, we stand together as a community.
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
March 11, 2025 at 3:10 PM
At the Stand up for science protest yesterday. There was anger, there was determination. As researchers, clinicians, and activists, we stand together as a community.
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
March 10, 2025 at 6:48 PM
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
